Skip to main content
Clinical Trials/NCT05239845
NCT05239845Active, not recruitingNot Applicable

Evaluating the Effects of Prebiotic-based Interventions on Sleep, the Gut Microbiome, Cognition, Immune Function and Stress Following 56 Days Consumption in Healthy Volunteers

Northumbria University2 sites in 1 country68 target enrollmentStarted: March 3, 2022Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Enrollment
68
Locations
2
Primary Endpoint
Lab-recorded polysomnography- Sleep Quality

Study Overview

Brief Summary

The aim of the proposed randomised, double-blind, controlled, parallel groups trial is to assess the sleep, gut microbiome, cognitive, immune and stress effects of 56 days administration of three formulations of a prebiotic-based intervention, in comparison to a placebo control, in a cohort of healthy adults reporting poor sleep quality.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Other
Masking
Triple (Participant, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
25 Years to 60 Years (Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Participants must self-assess themselves as being in good health.
  • Have a stable sleep/wake schedule (bedtime between 9pm and 1am and wake time between 6am and 10am at least 5 nights per week)
  • Aged 25 to 60 years at the time of randomisation
  • Fluent in English
  • Identify as a 'poor sleeper' as defined subjectively (i.e. poor sleep quality, unrefreshing sleep) and a total score of >5 on the Pittsburgh Sleep Quality Index (PSQI).

Exclusion Criteria

  • Member of own household currently participating in this trial
  • Evidence of current or recent sleep disorders (e.g. sleep apnoea, insomnia, circadian rhythm disorders), taking any medication which exerts sedative effects, affects the CNS and/or sleep, or be currently unwell with any illness that affects sleep (i.e. disorders of the CNS). An initial screening for sleep disorders will be conducted using the Sleep Disorders Symptom Checklist-25 (SDS-CL; Klingman et al., 2017). If a participant reports positively to any of the 25 questions in terms of being affected for three nights per week, or more, this will be followed up using a clinical interview according to the International Classification of Sleep Disorders (ICSD-3) to exclude on the basis of a sleep disorder
  • History of seizures or epilepsy
  • Shift working or have a history of shift work within the previous six months
  • Currently, or within the previous 8 weeks, consuming any prebiotic or probiotic products/supplements (including specifically oligosaccharides)
  • Participation in any other intervention research trials
  • Sleeping at a location other than their usual residence more than two nights per week during participation
  • Travel across multiple time zones within the last three months or have planned travel across multiple time zones during the study
  • Current or recent mood disturbances or Axis I disorders
  • Current misuse of alcohol and/or drugs
  • Current smoker
  • Recent (within the last 12 weeks) infection and/or use of antibiotic medication
  • Pregnant, seeking to become pregnant or lactating
  • Those using (including within the last 2 weeks) proton-pump inhibitors
  • Milk allergy

Arms & Interventions

Investigational Supplement 1 (INV-1)

Active Comparator

The total daily supplement to be consumed by participants is 33.0 g. This will be administered as 2 separate doses mixed with water, a 16.5 g dose (two 8.25 g sachets) to be consumed in the morning (AM dose) and a 16.5 g dose (two 8.25 g sachets) to be consumed in the evening (PM dose). Supplementation will last 56 days.

Intervention: Prebiotic (Dietary Supplement)

Investigational Supplement 1 (INV-2)

Active Comparator

The total daily supplement to be consumed by participants is 33.0 g. This will be administered as 2 separate doses mixed with water, a 16.5 g dose (two 8.25 g sachets) to be consumed in the morning (AM dose) and a 16.5 g dose (two 8.25 g sachets) to be consumed in the evening (PM dose). Supplementation will last 56 days.

Intervention: Prebiotic (Dietary Supplement)

Investigational Supplement 1 (INV-3)

Active Comparator

The total daily supplement to be consumed by participants is 33.0 g. This will be administered as 2 separate doses mixed with water, a 16.5 g dose (two 8.25 g sachets) to be consumed in the morning (AM dose) and a 16.5 g dose (two 8.25 g sachets) to be consumed in the evening (PM dose). Supplementation will last 56 days.

Intervention: Prebiotic (Dietary Supplement)

Control

Placebo Comparator

The total daily supplement to be consumed by participants is 33.0 g. This will be administered as 2 separate doses mixed with water, a 16.5 g dose (two 8.25 g sachets) to be consumed in the morning (AM dose) and a 16.5 g dose (two 8.25 g sachets) to be consumed in the evening (PM dose). Supplementation will last 56 days.

Intervention: Control (Other)

Outcomes

Primary Outcomes

Lab-recorded polysomnography- Sleep Quality

Time Frame: Change from protocol days 2 and 3 (baseline) and 59 and 60 following 56 days of supplement consumption

percentage of time in staged sleep from total sleep recorded time

Secondary Outcomes

  • Lab-recorded polysomnography- Time spent in stages of rapid eye movement (REM) and non-REM sleep(Change from protocol days 2 and 3 (baseline) and 59 and 60 following 56 days of supplement consumption)
  • Lab-recorded polysomnography- Sleep onset latency(Change from protocol days 2 and 3 (baseline) and 59 and 60 following 56 days of supplement consumption)
  • Lab-recorded polysomnography- Total sleep time(Change from protocol days 2 and 3 (baseline) and 59 and 60 following 56 days of supplement consumption)
  • Lab-recorded polysomnography- Number of awakenings(Change from protocol days 2 and 3 (baseline) and 59 and 60 following 56 days of supplement consumption)
  • Lab-recorded polysomnography- Wake after sleep onset(Change from protocol days 2 and 3 (baseline) and 59 and 60 following 56 days of supplement consumption)
  • Lab-recorded polysomnography- REM Rebound(Change from protocol days 2 and 3 (baseline) and 59 and 60 following 56 days of supplement consumption)
  • Lab-recorded polysomnography- Sleep microstructure(Change from protocol days 2 and 3 (baseline) and 59 and 60 following 56 days of supplement consumption)
  • Actigraphy - Sleep onset latency(Change from baseline following 56 days of supplement consumption)
  • Actigraphy - Total sleep time(Change from baseline following 56 days of supplement consumption)
  • Actigraphy - Number of awakenings(Change from baseline following 56 days of supplement consumption)
  • Actigraphy - Wake after sleep onset (WASO)(Change from baseline following 56 days of supplement consumption)
  • Actigraphy - Sleep efficiency(Change from baseline following 56 days of supplement consumption)
  • Blood Pressure and Heart Rate (BP/HR)(Change from baseline following 56 days of supplement consumption)
  • Waist-to-Hip Ratio (WHR)(Change from baseline following 56 days of supplement consumption)
  • Work Productivity and Activity Impairment questionnaire (WPAI)(Change from baseline following 56 days of supplement consumption)
  • Gastrointestinal symptoms questionnaire(Change from baseline following 56 days of supplement consumption)
  • Sleep Diary -Sleep Latency(Change from baseline following 56 days of supplement consumption)
  • Sleep Diary - Wake After Sleep Onset (WASO)(Change from baseline following 56 days of supplement consumption)
  • Body Mass Index (BMI)(Change from baseline following 56 days of supplement consumption)
  • Perceived Stress Scale (PSS(Change from baseline following 56 days of supplement consumption)
  • Sleep Diary -Number of Awakenings(Change from baseline following 56 days of supplement consumption)
  • Dietary assessment- Intake24(Change from baseline following 56 days of supplement consumption)
  • Subjective Stress (VAS)(Change from baseline following 56 days of supplement consumption)
  • Subjective productivity (VAS)(Change from baseline following 56 days of supplement consumption)
  • Cognitive domain factor score(Change from baseline following 56 days of supplement consumption)
  • Cognitive Function under stressful conditions(Change from baseline following 56 days of supplement consumption)
  • Changes in subjective stress; as assessed by the 'state, trait anxiety inventory' (STAI)(Change from baseline following 56 days of supplement consumption)
  • Pittsburgh Sleep Quality Index (PSQI)(Change from baseline following 56 days of supplement consumption)
  • Profile of Mood States (POMS)(Change from baseline following 56 days of supplement consumption)
  • State-Trait Anxiety Inventory (STAI)(Change from baseline following 56 days of supplement consumption)
  • Depression, Anxiety and Stress Scale - 21 Items (DASS-21)(Change from baseline following 56 days of supplement consumption)
  • 12-Item Short Form Survey (SF-12)(Change from baseline following 56 days of supplement consumption)
  • Sleep Diary -Total Sleep Time(Change from baseline following 56 days of supplement consumption)
  • Sleep Diary -Time in bed(Change from baseline following 56 days of supplement consumption)
  • Sleep Diary - Sleep Efficiency(Change from baseline following 56 days of supplement consumption)
  • Sleep Diary - Sleep Quality(Change from baseline following 56 days of supplement consumption)
  • Perceived sleep quality (VAS)(Change from baseline following 56 days of supplement consumption)
  • Subjective mood (VAS)(Change from baseline following 56 days of supplement consumption)
  • COMPASS global performance measures(Change from baseline following 56 days of supplement consumption)
  • Changes in objective stress; as assessed by salivary cortisol levels(Change from baseline following 56 days of supplement consumption)
  • Changes in objective stress; as assessed by salivary alpha-amylase levels(Change from baseline following 56 days of supplement consumption)
  • Changes in objective stress; as assessed by galvanic skin response (GSR)(Change from baseline following 56 days of supplement consumption)
  • Changes in objective stress; as assessed by heart rate (HR)(Change from baseline following 56 days of supplement consumption)
  • Gut microbiome assessments (gut bacterial profile)(Change from baseline following 56 days of supplement consumption)
  • Immunological marker Assessment -Blood(Change from baseline following 56 days of supplement consumption)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials